Biotech Values

[DewDiligence]

OHRP -81% on Squalamine failure in AMD:

https://finance.yahoo.com/news/ohr-pharmaceutical-announces-efficacy-results-110000772.html

Subjects receiving squalamine combination therapy (n=119) achieved a mean gain of 8.33 letters from baseline versus 10.58 letters from baseline with Lucentis monotherapy (n=118).

I.e., adding Squalamine to Lucentis produced a numerically worse outcome than Lucentis alone.

Squalamine failed in AMD more than 10 years ago, when it was owned by Genaera (#msg-136498116). The compound is a weak, “natural” anti-angiogenesis agent that was never subjected to any optimization by medicinal chemists. OHRP claimed that it would work as an eye drop, but treating a back-of-the-eye disease such as wet AMD with a topical form of a weak agent only serves to makes the agent weaker.